Clinical Trial Update: Observational Study of Safety of Flu Cell Culture Derived Adjuvanted Swine Origin A (H1N1) Pandemic Subunit Vaccine

View source ↗

Summary

Observational safety study of Novartis Vaccines' cell culture-derived, adjuvanted swine-origin A/H1N1 pandemic subunit influenza vaccine has completed, summariz…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Influenza Virus Infection Subtype H1n1

Drugs mentioned

• Penza (influenza vaccine, cell culture-derived, adjuvanted, H1N1)

Snippet

Sponsor: Novartis Vaccines | Conditions: Novel Influenza A (H1N1), A New Flu Virus of Swine Origin | Status: COMPLETED